Dennis Ding
About Dennis Ding
Dennis Ding is the Vice President and Equity Research Analyst at Jefferies, with extensive experience in biotechnology and medical devices sectors.
Current Position at Jefferies
Dennis Ding currently serves as Vice President and Equity Research Analyst at Jefferies. He transitioned to this role in 2022. Ding's portfolio in this capacity includes a diverse range of biotech companies such as ABUS, ARDX, ASMB, CARA, ESPR, LYRA, MIST, NAMS, NGM, PRDS, ROIV, and VERU. His role involves rigorous analysis and research on these companies to provide insights for investors.
Previous Experience at Jefferies
Before becoming Vice President, Dennis Ding was a Senior Associate in Equity Research Biotechnology at Jefferies from 2020 to 2022. Based in New York, he specialized in the biotechnology sector, where he conducted in-depth research and analysis to support senior analysts and provide recommendations. His tenure helped refine his expertise in biotechnology equities.
Experience at Mizuho
From 2018 to 2020, Dennis Ding worked as an Associate in Equity Research Biotechnology at Mizuho in New York. In this role, Ding contributed to the analysis of biotech companies, aiding in the development of research reports and investment recommendations. This experience further solidified his credentials in the biotechnology sector.
Academic Background
Dennis Ding's academic journey includes a Medicine degree from Albany Medical College, completed between 2013 and 2017. He also holds a Master of Engineering (MEng) and a Bachelor of Engineering (BE) in Bioengineering and Biomedical Engineering from the University of Pennsylvania. His comprehensive education provided a strong foundation for his subsequent research and analytical roles in the medical and biotechnology fields.
Early Research Roles
Dennis Ding's early career includes various research positions. He worked as a Research Intern at the Penn Genome Frontier Institute, a Research Assistant at the University of Pennsylvania's Department of Biology and Institute for Medicine and Engineering, and a Research Coordinator at the University's Laboratory of Innovative and Translational Nursing Research. These roles, spanning from 2009 to 2013, were integral in shaping his research skills and technical knowledge in biomedical sciences.